TY - JOUR
T1 - Risks of Adverse Events in Advanced CKD
T2 - The Chronic Renal Insufficiency Cohort (CRIC) Study
AU - on behalf of the
AU - CRIC Study Investigators
AU - CRIC Study Investigators
AU - Grams, Morgan E.
AU - Yang, Wei
AU - Rebholz, Casey M.
AU - Wang, Xue
AU - Porter, Anna C.
AU - Inker, Lesley A.
AU - Horwitz, Edward
AU - Sondheimer, James H.
AU - Hamm, L. Lee
AU - He, Jiang
AU - Weir, Matthew R.
AU - Jaar, Bernard G.
AU - Shafi, Tariq
AU - Appel, Lawrence J.
AU - Hsu, Chi yuan
AU - Feldman, Harold I.
AU - Go, Alan S.
AU - Kusek, John W.
AU - Lash, James P.
AU - Ojo, Akinlolu
AU - Rahman, Mahboob
AU - Townsend, Raymond R.
N1 - Funding Information:
Support: Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award (CTSA; National Institutes of Health [NIH]/National Center for Advancing Translational Sciences [NCATS] UL1TR000003), Johns Hopkins University UL1 TR-000424, University of Maryland General Clinical Research Center M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane Center of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, and Kaiser Permanente NIH/National Center for Research Resources University of California San Francisco−Clinical and Translational Science Institute UL1 RR-024131. In addition, Drs Grams and Hsu have received support for this project from the NIDDK (K08DK092287 and R01DK70939, respectively). None of the funders had any role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.
Publisher Copyright:
© 2017 National Kidney Foundation, Inc.
PY - 2017/9
Y1 - 2017/9
N2 - Background People with advanced chronic kidney disease are at risk for the development of end-stage renal disease (ESRD), but also many other adverse outcomes, including cardiovascular disease (CVD) events and death. Determination of risk factors that explain the variability in prognosis and timing of these adverse outcomes can aid patient counseling and medical decision making. Study Design Prospective research cohort. Setting & Participants 1,798 participants with estimated glomerular filtration rates (eGFRs) < 30 mL/min/1.73 m2 in the CRIC Study were followed up for a median of 5.5 years. Predictors Age, race, sex, eGFR, proteinuria, diabetes mellitus, body mass index, ejection fraction, systolic blood pressure, history of CVD, and smoking history. Outcomes ESRD, CVD (congestive heart failure, stroke, myocardial infarction, and peripheral artery disease), and death. Results Baseline age of the cohort was 60 years, 46% were women, and 46% were African American. Although 52.3% of participants progressed to ESRD during follow-up, the path by which this occurred was variable. For example, predicted 1-year probabilities for a hypothetical 60-year-old white woman with eGFR of 30 mL/min/1.73 m2, urine protein excretion of 1.8 g/d, and no diabetes or CVD (risk characteristics similar to the average participant) were 3.3%, 4.1%, and 0.3%, for first developing CVD, ESRD, and death, respectively. For a 40-year-old African American man with similar characteristics but higher systolic blood pressure, the corresponding 1-year probabilities were 2.4%, 13.2%, and 0.1%. For all participants, the development of ESRD or CVD increased the risk for subsequent mortality, with no differences by patient race or body mass index. Limitations The CRIC population was specifically recruited for kidney disease, and the vast majority had seen a nephrologist. Conclusions The prognosis and timing of adverse outcomes in chronic kidney disease vary by patient characteristics. These results may help guide the development of personalized approaches for managing patients with advanced CKD.
AB - Background People with advanced chronic kidney disease are at risk for the development of end-stage renal disease (ESRD), but also many other adverse outcomes, including cardiovascular disease (CVD) events and death. Determination of risk factors that explain the variability in prognosis and timing of these adverse outcomes can aid patient counseling and medical decision making. Study Design Prospective research cohort. Setting & Participants 1,798 participants with estimated glomerular filtration rates (eGFRs) < 30 mL/min/1.73 m2 in the CRIC Study were followed up for a median of 5.5 years. Predictors Age, race, sex, eGFR, proteinuria, diabetes mellitus, body mass index, ejection fraction, systolic blood pressure, history of CVD, and smoking history. Outcomes ESRD, CVD (congestive heart failure, stroke, myocardial infarction, and peripheral artery disease), and death. Results Baseline age of the cohort was 60 years, 46% were women, and 46% were African American. Although 52.3% of participants progressed to ESRD during follow-up, the path by which this occurred was variable. For example, predicted 1-year probabilities for a hypothetical 60-year-old white woman with eGFR of 30 mL/min/1.73 m2, urine protein excretion of 1.8 g/d, and no diabetes or CVD (risk characteristics similar to the average participant) were 3.3%, 4.1%, and 0.3%, for first developing CVD, ESRD, and death, respectively. For a 40-year-old African American man with similar characteristics but higher systolic blood pressure, the corresponding 1-year probabilities were 2.4%, 13.2%, and 0.1%. For all participants, the development of ESRD or CVD increased the risk for subsequent mortality, with no differences by patient race or body mass index. Limitations The CRIC population was specifically recruited for kidney disease, and the vast majority had seen a nephrologist. Conclusions The prognosis and timing of adverse outcomes in chronic kidney disease vary by patient characteristics. These results may help guide the development of personalized approaches for managing patients with advanced CKD.
KW - CKD progression
KW - CRIC (Chronic Renal Insufficiency Cohort)
KW - Chronic kidney disease (CKD)
KW - advanced CKD
KW - adverse event
KW - cardiovascular disease (CVD)
KW - disease trajectory
KW - end-stage renal disease (ESRD)
KW - incident ESRD
KW - kidney function decline
KW - mortality
KW - pre-ESRD death
KW - prognosis
KW - risk factor
UR - http://www.scopus.com/inward/record.url?scp=85016461053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016461053&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.01.050
DO - 10.1053/j.ajkd.2017.01.050
M3 - Article
C2 - 28366517
AN - SCOPUS:85016461053
VL - 70
SP - 337
EP - 346
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
IS - 3
ER -